PNC Financial Services Group Inc. Decreases Stock Holdings in IQVIA Holdings Inc. $IQV

PNC Financial Services Group Inc. lessened its stake in IQVIA Holdings Inc. (NYSE:IQV) by 6.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 46,537 shares of the medical research company’s stock after selling 3,173 shares during the quarter. PNC Financial Services Group Inc.’s holdings in IQVIA were worth $8,839,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. HighTower Advisors LLC raised its position in shares of IQVIA by 30.2% during the 3rd quarter. HighTower Advisors LLC now owns 8,701 shares of the medical research company’s stock worth $1,653,000 after purchasing an additional 2,019 shares during the last quarter. GF Fund Management CO. LTD. increased its stake in IQVIA by 6.4% during the 3rd quarter. GF Fund Management CO. LTD. now owns 4,518 shares of the medical research company’s stock worth $858,000 after buying an additional 271 shares in the last quarter. Coronation Fund Managers Ltd. raised its holdings in shares of IQVIA by 382.5% during the third quarter. Coronation Fund Managers Ltd. now owns 69,434 shares of the medical research company’s stock valued at $13,188,000 after acquiring an additional 55,043 shares during the last quarter. Florida Financial Advisors LLC lifted its position in shares of IQVIA by 14.2% in the third quarter. Florida Financial Advisors LLC now owns 1,485 shares of the medical research company’s stock valued at $282,000 after acquiring an additional 185 shares in the last quarter. Finally, CENTRAL TRUST Co boosted its stake in shares of IQVIA by 15.9% in the third quarter. CENTRAL TRUST Co now owns 1,396 shares of the medical research company’s stock worth $265,000 after acquiring an additional 191 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

IQV stock opened at $171.07 on Thursday. The business has a 50 day moving average price of $219.87 and a 200 day moving average price of $208.67. The company has a quick ratio of 0.70, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock has a market cap of $29.13 billion, a price-to-earnings ratio of 21.76, a PEG ratio of 1.58 and a beta of 1.37. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the company earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Mizuho set a $266.00 price objective on IQVIA in a report on Friday, January 9th. BMO Capital Markets set a $250.00 target price on IQVIA in a research note on Friday, February 6th. Truist Financial lifted their price target on shares of IQVIA from $265.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. TD Cowen upped their price objective on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. dropped their target price on IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $238.20.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.